ABBOTT PARK, Ill.,
Aug. 18, 2014
/PRNewswire/ -- Abbott (NYSE: ABT) and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi-phased approach, the tests would be developed for Abbott's i-
System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members.  With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.
To view the multimedia assets associated with this release, please click
"The quick and accurate diagnosis of a concussion is critical so that soldiers who are affected--whether on the battlefield or not--can be removed from duty to recover and to prevent further injury," said Colonel
Dallas C. Hack
, M.D., Brain Health Coordinator, United States Army Medical Research and Materiel Command. "The Department of Defense collaboration with Abbott represents a major initiative to help improve efforts to understand this complex injury and care for wounded warriors suffering from this condition."
Research suggests that certain proteins are released in the bloodstream following a brain injury, such as a concussion. Data have shown that detecting a mild traumatic brain injury can be difficult since imaging technology may not show abnormalities and symptoms can be similar to or mistaken for other medical conditions. ,